| Date | Name | Shares | Transaction | Value |
|---|
|
Aug 16, 2024
| Roland Goette EVP and President EMEA |
N/A
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
|
Aug 16, 2024
| Roland Goette EVP and President EMEA |
12,585
| Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $234.08 per share |
2,945,896.80
|
|
Aug 16, 2024
| Roland Goette EVP and President EMEA |
16,603
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $132.54 per share |
2,200,561.62
|
|
Jul 3, 2024
| Thomas J. Spoerel SVPController & Chief Acct Off |
1,928
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 |
0.00
|
|
May 17, 2024
| Roland Goette EVP and President EMEA |
11,308
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $237.46 per share |
2,685,197.68
|
|
May 8, 2024
| Christopher Ian Montague Jones Director |
9,954
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
May 8, 2024
| Carrie L. Byington Director |
1,162
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
May 2, 2024
| Michael David Garrison EVP & President Medical |
5,381
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $232.81 per share |
1,252,750.61
|
|
Apr 8, 2024
| Shana Carol Neal EVP and Chief People Officer |
16,389
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 |
0.00
|
|
Mar 6, 2024
| Antoine Ezell EVP, President NA & CMO |
9,320
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 |
0.00
|
|
Dec 1, 2023
| Richard Byrd EVP & President Interventional |
4,120
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $238.47 per share |
982,496.40
|
|
Nov 29, 2023
| Thomas E. Polen Chairman, CEO and President |
71,811
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 |
0.00
|
|
Nov 29, 2023
| Thomas E. Polen Chairman, CEO and President |
63,335
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Nov 29, 2023
| Thomas E. Polen Chairman, CEO and President |
70,855
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Nov 29, 2023
| Richard Byrd EVP & President Interventional |
6,276
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 |
0.00
|
|
Nov 29, 2023
| Richard Byrd EVP & President Interventional |
7,785
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Nov 29, 2023
| Michael David Garrison EVP & President Medical |
10,364
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Nov 29, 2023
| Thomas E. Polen Chairman, CEO and President |
59,089
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Nov 29, 2023
| Shana Carol Neal EVP and Chief People Officer |
9,190
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Nov 29, 2023
| Christopher J. DelOrefice EVP & Chief Financial Officer |
14,324
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|